Abstract:Objective: To report on the two years outcome of Chinese multi-center study of the treatment of high risk non-calcified pure aortic regurgitation with transcatheter heart valve replacement (TAVR) using domestic made J-Valve™ system. Methods: The national multi-center clinical study of the treatment of high risk non-calcified pure aortic regurgitation with transcatheter heart valve replacement using domestic made J-Valve™ system was conducted during the period from April 2014 to July 2015. The follow-up time was up to 2 years. Forty-three cases with predominant aortic valve regurgitation were enrolled for transapical implantation of the J-Valve™ system from 3 Chinese centers, including 16 patients from Zhongshan Hospital, Fudan University, 23 patients from West China Hospital, Sichuan University, and 4 patients from Fuwai Cardiovascular Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. There were 30 males and 13 females in this cohort. The age of the patients was (74±6) years (range: 61 to 84 years). The patiens were all sympotmatic preoperatively. All patients were considered at prohibitive or high risk for surgical valve replacement (Logistic European System for Cardiac Operative Risk Evaluation of (25.5±5.3)%, range: 20.0% to 44.4%) after evaluation by an interdisciplinary heart team. Comprehensive clinical and echocardiographic assessments were scheduled before discharge and at 30 days, 12 months, and 24 months after the procedure. Results: One patients was converted to surgical aortic valve replacement (SAVR) due to valve embolism into the arch. The other 42 cases had J-Valve™ systems implanted successfully. One patient died from multi-organ disorder due to paravalvular leak (PVL) during perioperative period. There was no acute myocardial infarction, stroke or coronary obstruction during the perioperative period. The median follow-up time was 725 days (range: 6 to 1 082 days). There were 5 patients died during the 2 years, follow-up, 2 patients had stroke, 2 patients had permanent pacemaker implanted. Three patients had valve related reinterventions: One for intraoperative valve embolism into the aortic arch followed by a conversion to SAVR which was mentioned above. One patient underwent SAVR on the postoperative day 6 due to moderate PVL and ventricular dysfunction. One patient underwent SAVR 6 months after primary procedure due to prosthesis thrombosis and severe aortic valve stenosis.Thirty-six patients with J-valve™ implanted survived to the latest echocardiogram follow-up, 25 patients had trivial or less PVL, 9 patients had mild PVL, and the transvalvular gradient after valve implantation was favorable at (9.8±5.8) mmHg (1 mmHg=0.133 kPa). Conclusions: Transapical implantation of domestic made J-Valve™ transcatheter heart valve system for patients with predominant aortic regurgitation has a excellent early outcome. This novel technology is safe and effective.

Early and mid-term results after 17 mm St.Jude Medical Regent mechanicalvalve replacement in patients with small aortic valve ring

[Early and Mid-Term Results after 17 Mm St Jude Regent Mechanical Valve Replacement in 44 Patients with Small Aortic Root].

Application of Regent Mechanical Valve in Patients with Small Aortic Annulus: 3-Year Follow-Up.

Comparison of Aortic Annulus Dimensions by Multimodal Measurement Before Transcatheter Aortic Valve Replacement

Replacement of the st jude medical regent valve in the aortic position with a continuous suture technique in the small aortic root.

[Comparison of Aortic Annular Diameter Defined by Different Measurement Mordalities Before Transcatheter Aortic Valve Implantation].

Transapical aortic valve implantation using J-Valve? system for high-risk patients with aortic regurgitation: mid-stage of 1 year follow-up

Short-Term Outcomes after Transcatheter Aortic Valve Replacement in Predominant Aortic Regurgitation with Left Ventricular Dysfunction.

Comparing Study of Heart Function of Biological Valves Replacement with Mechanical Valves Replacement in Patients with Small Aortic Root

Doppler Echocardiographyic Evaluation of Heart Function in Patients with Small Aortic Vale Replacement

A New Transcatheter Aortic Valve Replacement System for Predominant Aortic Regurgitation Implantation of the J-Valve and Early Outcome

30-Day Outcomes after Surgical or Transapical Aortic Valve Replacement in Symptomatic Aortic Regurgitation

Sutureless Aortic Valve Replacement vs. Transcatheter Aortic Valve Implantation in Patients with Small Aortic Annulus: Clinical and Hemodynamic Outcomes from a Multi-Institutional Study

Transcatheter aortic valve implantation for severe aortic regurgitation using the J-Valve system: A midterm follow-up study

Performance of the 32 mm Myval transcatheter heart valve for treatment of aortic stenosis in patients with extremely large aortic annuli in real-world scenario: First global, multicenter experience

Transapical Transcatheter Aortic Valve Replacement for Aortic Regurgitation with a Second-Generation Heart Valve.

Transapical Transcatheter Aortic Valve Replacement with a Novel Transcatheter Aortic Valve Replacement System in High-Risk Patients with Severe Aortic Valve Diseases.

Impact of Small Aortic Annuli on the Performance of Transcatheter Aortic Valve Replacement Bioprostheses: An Updated Meta-Analysis of Recent Studies

Transapical Transcatheter Valve Replacement Using J-Valve for Aortic Valve Diseases

Long-Term Clinical Outcomes of Transcatheter Aortic Valve Replacement Using J-Valve System for Patients with Pure Native Aortic Regurgitation

Transapical Transcatheter Aortic Valve Replacement for High Risk Pure Non-Calcified Aortic Regurgitation: Two Years Outcome of a Multi-Center Study